Edition:
United States

PLx Pharma Inc (PLXP.OQ)

PLXP.OQ on NASDAQ Stock Exchange Capital Market

6.45USD
2:09pm EST
Change (% chg)

$-0.20 (-3.01%)
Prev Close
$6.65
Open
$6.55
Day's High
$6.60
Day's Low
$6.45
Volume
855
Avg. Vol
4,475
52-wk High
$21.60
52-wk Low
$5.60

Summary

Name Age Since Current Position

Rita O'Connor

49 2017 Chief Financial Officer

Robert Shawah

49 2014 Chief Accounting Officer, Treasurer

Steven Valentino

2017 Vice President - Trade Sales

Tom Long

2017 Vice President - Manufacturing & Technical Operations

Gary Balkema

2017 Director

Kirk Calhoun

2017 Director

Robert Casale

2017 Director

Natasha Giordano

56 2017 Director

John Hadden

2017 Director

Michael Valentino

2017 Director

Biographies

Name Description

Rita O'Connor

Ms. Rita M. O’Connor, CPA, has been appointed has Chief Financial Officer of the Company., effective July 1, 2017. She joins PLx from the Kent Place School, an all-girls college preparatory school, where she has served as CFO since 2013. Ms. O’Connor served as CFO and Chief Information Officer at Xanodyne Pharmaceuticals from 2009 to 2012, and as Chief Financial Officer and Treasurer, from 2007 to 2008, of Adams Respiratory Therapeutics, where she previously served as Senior Vice President and Corporate Controller (2006–2007), Vice President and Controller (2005–2006), and Executive Director, Controller (2004–2005). Earlier in her career she held positions of increasing responsibility during an eight-year tenure at Schering-Plough Corporation, and began her career at Deloitte and Touche. Ms. O'Connor is a licensed certified public accountant and earned her Bachelor of Science in Accounting from Rutgers University. The PLx Board of Directors believes that Ms. O’Connor’s industry experience will enhance PLx’s commercial operations as well as its finance and accounting functions.

Robert Shawah

Robert G. Shawah, CPA is the Chief Accounting Officer, Treasurer of the company. From 2005 to 2013, Mr. Shawah served as a Vice President of Baldwin Pearson & Co., Inc. focusing on structuring transactions in the commercial and industrial real estate market in Fairfield County, Connecticut, as well as financial reporting responsibility. From 1997 to 2005, he served Sales and Financial Engineer for CC1 Inc., a private New Hampshire firm that designed and manufactured camera-based technical equipment for the printing industry. Prior to 1997, Mr. Shawah held financial management positions at Victorinox/Swiss Army Brands and Grace Cocoa, a division of W.R. Grace. His responsibilities at these firms included accounting, financial reporting, and foreign currency transactions. Mr. Shawah is a certified public accountant in the Commonwealth of Pennsylvania (inactive) and spent the first five years of his career in the audit division of Arthur Andersen LLP. Mr. Shawah received his Bachelors of Science degree in Business Administration from Bucknell University.

Steven Valentino

Mr. Steven Valentino has been appointed as Vice President - Trade Sales of the Company effective October 1, 2017. Mr. Valentino is a highly-credentialed executive with over 25 years of experience in the OTC and consumer healthcare space. His experience includes Rx to OTC switches, brand management, trade sales and operations and customer development across Drug, Mass Food and Specialty. He has held positions of increasing responsibility at Warner Lambert Consumer Health, Pfizer Consumer Healthcare and the Johnson & Johnson Consumer Companies. Most recently, Steven Valentino served as Vice President of Crossmark Drug, a division of Crossmark, where he was responsible for drug wholesale, dollar and retail merchandising for brand and private label products.

Tom Long

Mr. Tom Long serves as Vice President - Manufacturing & Technical Operations of the Company. Most recently, Mr. Long has independently consulted in building manufacturing and technical operations for several manufacturers large and small. Mr. Long served as Senior Vice President and General Manager, Manufacturing and Operations, for Adams Respiratory Therapeutics, Inc., where he managed the overall supply of Mucinex, Mucinex DM and Mucinex D, increasing productivity and meeting quality objectives. For more than 17 years, he had various responsibilities including materials management, international manufacturing, process engineering, production planning, inventory control, materials control, quality engineering, as well as pharmaceutical manufacturing and packaging.

Gary Balkema

Kirk Calhoun

Robert Casale

Natasha Giordano

Ms. Natasha Giordano is Director of the Company. Ms. Giordano was appointed PLx’s President and Chief Executive Officer and a director of PLx effective January 1, 2016, per the terms of her employment agreement. Previously, Ms. Giordano served as the Interim Chief Executive Officer of ClearPoint Learning, Inc., a position she held from May 2015 through November 2015. She also served on the ClearPoint board of directors from December 2009 through November 2015. Previously, Ms. Giordano served as the Chief Executive Officer of Healthcare Corporation of America from January 2014 through August 2014. From June 2009 to August 2012, Ms. Giordano served as Chief Operating Officer and then as Chief Executive Officer, President and a member of the board of directors of Xanodyne Pharmaceuticals, Inc. a branded specialty pharmaceutical company with development and commercial capabilities focused on pain management. Prior to that, she served as President, Americas, for Cegedim Dendrite (formerly Dendrite International Inc.) from 2007 to 2008 and as Senior Vice President of the Global Customer Business Unit of Cegedim Dendrite from 2004 to 2007. She had been with Cegedim Dendrite since 2000 and served as Group President for Global Business Unit for major customers, and Vice President of Global Sales. Earlier in her career, she worked nine years with Parke-Davis, then owned by Warner Lambert, in several sales and marketing positions including Strategic Alliance management and Sales Integration. Ms. Giordano holds a Bachelor of Science degree in nursing from Wagner College.

John Hadden

Michael Valentino

Mr. Michael J. Valentino is Director of the Company. Mr. Valentino has served as Executive Chairman of the board of directors of PLx since July 2011 and brings over 30 years of experience in the healthcare industry, including a broad range of critical leadership positions at both major pharmaceutical companies and venture backed start-ups. He previously served as President and Chief Executive Officer of Xanodyne Pharmaceuticals, Inc. from June 2009 to May 2010. From June 2003, Mr. Valentino successfully built start-up Adams Respiratory Therapeutics into a fully integrated specialty pharmaceutical company with more than $490 million in annual revenue and leading OTC brands such as Mucinex® and Delsym®. Under his leadership, Adams completed its initial public offering in July 2005, which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005, and in December 2007, the Company entered into a definitive agreement under which it would be acquired by Reckitt Benckiser, a world leader in household cleaning, health and personal care, for approximately $2.3 billion. Previously, Mr. Valentino was President and Chief Operating Officer at Alpharma, a leading global generic pharmaceutical company. Prior to joining Alpharma, he served as Executive Vice President, Global Head Consumer Pharmaceuticals for Novartis AG. He earlier served as President and Chief Operating Officer of Novartis Consumer Healthcare, North America. Mr. Valentino was also President of Pharmacia & Upjohn’s Consumer Products Division. Throughout his career, Mr. Valentino has been at the forefront of seven major prescription to OTC switches including such well known consumer brands as Benadryl®, Rogaine Extra Strength®, Motrin Jr.®, Nasalcrom®, Lamisil®, Voltaren (EU) and Mucinex®. He has served as Chairman of the Consumer Healthcare Products Association.